These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 12009270)
61. Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients. Cheng FW; Ip M; Chu YY; Lin Z; Lee V; Shing MK; Leung WK; Yuen PM; Li CK Arch Dis Child; 2012 Apr; 97(4):358-60. PubMed ID: 21109505 [TBL] [Abstract][Full Text] [Related]
62. Development of pneumococcal vaccines over the last 10 years. Principi N; Esposito S Expert Opin Biol Ther; 2018 Jan; 18(1):7-17. PubMed ID: 29022363 [TBL] [Abstract][Full Text] [Related]
63. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines. de Velasco EA; Merkus D; Anderton S; Verheul AF; Lizzio EF; Van der Zee R; Van Eden W; Hoffman T; Verhoef J; Snippe H Infect Immun; 1995 Mar; 63(3):961-8. PubMed ID: 7532630 [TBL] [Abstract][Full Text] [Related]
64. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Fry AM; Zell ER; Schuchat A; Butler JC; Whitney CG Vaccine; 2002 Dec; 21(3-4):303-11. PubMed ID: 12450706 [TBL] [Abstract][Full Text] [Related]
65. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide-CRM(197) conjugates induce protection against Streptococcus pneumoniae type 3 in mice. Benaissa-Trouw B; Lefeber DJ; Kamerling JP; Vliegenthart JF; Kraaijeveld K; Snippe H Infect Immun; 2001 Jul; 69(7):4698-701. PubMed ID: 11402020 [TBL] [Abstract][Full Text] [Related]
66. B cell mediated priming following pneumococcal colonization. Rabquer B; Shriner AK; Smithson SL; Westerink MA Vaccine; 2007 Mar; 25(11):2036-42. PubMed ID: 17240006 [TBL] [Abstract][Full Text] [Related]
67. Mucosal immunization with PsaA protein, using chitosan as a delivery system, increases protection against acute otitis media and invasive infection by Streptococcus pneumoniae. Xu JH; Dai WJ; Chen B; Fan XY Scand J Immunol; 2015 Mar; 81(3):177-85. PubMed ID: 25565478 [TBL] [Abstract][Full Text] [Related]
68. Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides. Boudewijns M; Jeurissen A; Wuyts M; Moens L; Boon L; Van Neerven JJ; Kasran A; Overbergh L; Lenaerts C; Waer M; Mathieu C; Ceuppens JL; Bossuyt X J Leukoc Biol; 2005 Nov; 78(5):1060-9. PubMed ID: 16081596 [TBL] [Abstract][Full Text] [Related]
69. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Breukels MA; Zandvoort A; van Den Dobbelsteen GP; van Den Muijsenberg A; Lodewijk ME; Beurret M; Klok PA; Timens W; Rijkers GT Infect Immun; 2001 Dec; 69(12):7583-7. PubMed ID: 11705936 [TBL] [Abstract][Full Text] [Related]
71. Revised interpretation of the immunological results obtained with pneumococcal polysaccharide 17F derived synthetic di-, tri- and tetrasaccharide conjugates in mice and rabbits. Jansen WT; Verheul AF; Veeneman GH; van Boom JH; Snippe H Vaccine; 2001 Oct; 20(1-2):19-21. PubMed ID: 11567741 [TBL] [Abstract][Full Text] [Related]
72. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Alonso de Velasco E; Verheul AF; Veeneman GH; Gomes LJ; van Boom JH; Verhoef J; Snippe H Vaccine; 1993 Nov; 11(14):1429-36. PubMed ID: 8310762 [TBL] [Abstract][Full Text] [Related]
73. Generation of antibody responses to pneumococcal capsular polysaccharides is independent of CD1 expression in mice. Moens L; Jeurissen A; Nierkens S; Boon L; Van Kaer L; Kasran A; Wuyts G; Ceuppens JL; Bossuyt X Infect Immun; 2009 May; 77(5):1976-80. PubMed ID: 19188354 [TBL] [Abstract][Full Text] [Related]
74. T Cell-Mediated Humoral Immune Responses to Type 3 Capsular Polysaccharide of Middleton DR; Sun L; Paschall AV; Avci FY J Immunol; 2017 Jul; 199(2):598-603. PubMed ID: 28566369 [TBL] [Abstract][Full Text] [Related]
75. On the immunogenicity of ribosomes and ribosomal proteins isolated from Klebsiella pneumoniae and Streptococcus pneumoniae. Robert D; Michel S; Ivanoff B; Cozzone AJ; Fontanges R Microbiol Immunol; 1981; 25(2):183-94. PubMed ID: 7015078 [TBL] [Abstract][Full Text] [Related]
77. Evidence that L-rhamnose is the antigenic determinant of hyporesponsiveness of BALB/c mice to Klebsiella pneumoniae type 47. White-Scharf ME; Rosenberg LT Infect Immun; 1978 Oct; 22(1):18-21. PubMed ID: 83296 [TBL] [Abstract][Full Text] [Related]
78. Noncovalent association of protein and capsular polysaccharide on bacteria-sized latex beads as a model for polysaccharide-specific humoral immunity to intact gram-positive extracellular bacteria. Colino J; Duke L; Snapper CM J Immunol; 2013 Sep; 191(6):3254-63. PubMed ID: 23926322 [TBL] [Abstract][Full Text] [Related]
79. In silico and in vivo Investigations of the Immunoreactivity of Klebsiella pneumoniae OmpA Protein as a Vaccine Candidate. Shahbazi S; Badmasti F; Habibi M; Sabzi S; Noori Goodarzi N; Farokhi M; Asadi Karam MR Iran Biomed J; 2024 Jul; 28(4):156-67. PubMed ID: 38946021 [TBL] [Abstract][Full Text] [Related]
80. Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host. Peng Z; Wu J; Wang K; Li X; Sun P; Zhang L; Huang J; Liu Y; Hua X; Yu Y; Pan C; Wang H; Zhu L Adv Sci (Weinh); 2021 Jul; 8(14):e2100549. PubMed ID: 34032027 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]